The impact of dual-versus single-chamber implantable cardioverter-defibrilltor implantation on survival  by Gold, Michael et al.
138A ABSTRACTS - Cardiac Arrhythmias JACC March 19,2003 
9:15 a.m 
873-4 Prospective Randomized Comparison of Rectilinear 
Biphasic Waveform Shock Versus Truncated 
Exponential Biphasic Waveform Shock for 
Transthoracic Cardioversion of Atrial Fibrillation 
Soo G. Kim, Maureen Kim, David Park, Jay N. Gross, Kevin J. Ferrick, Eugen Patma, 
John D. Fisher, Montefiore Medical Center, Bronx, NY, Albert Einstein College of 
Medicine, Bronx, NY 
Background: A defibrillator using rectilinear biphasic waveform (2011) reportedly requires 
lower energy for defibdllation than a device using truncated exponential biphasic wave- 
form (Physio). Success rates for cardioversion of atrial fibrillation (AF) were compared 
between Zoll (with a maximum energy of 2OOJ) and Physio (with a maximum energy of 
360J). 
Methods: Patients (pts) undergoing transthoracic cardioversion for AF were randomly 
assigned to Zoll or Physio. Shock energy was increased stepwise (5OJ, lOOJ, 15OJ, 
200J) until cardioversion or to the maximum level of the device. If AF persisted despite 
the maximum energy shock, pts were crossed over and received the maximum energy 
shock by the other device. 
Results: Of 134 pts (76 males, age 64+/-15). 63 were assigned to Zoll and 71 to Physio. 
The 2 groups were similar with regard to height, weight, body surface area, and duration 
of AF. Cummulative conversion rates at each energy level are compared in the Table. 
Two pts in Zoll group who did not convert with a 200J shock crossed over and converted 
after a 360J shock by Physio. Two in Physio group who did not convert with a 360J shock 
crossed over but did not convert with a 206J shock by Zoll. 
Conclusions: Using biphasic defibrillators, AF could be convened in 97% of pts by tran- 
sthoracic method. At energy levels tested, success rates were not significantly different 
between the 2 devices. In rare cases, a 360J shock with Physio may be successful when 
a 200J shock with Zoll (the maximum energy) fails to restore sinus rhythm. 
50J 1 OOJ 15OJ 2oOJ 360J 
Physio 55%(39 Of 83%(59 of 92%(65 of 97%(69 of 97%(69 of 
(n=71) 71) 71) 71) 71) 71) 
Zoll (n=63) 59%(37 of 76%(46 of 92%(56 of 97%(61 of not available 
63) 63) 63) 63) 
p-value 0.70 0.29 0.94 0.69 
9:30 a.m. 
873-5 Cost Analysis of Implantable Cardioverter Defibrillators 
in Patients With lschemic Heart Disease, Decreased Left 
Ventricular Function, and Nonsustained Ventricular 
Tachycardia: Selective or Widespread Use? 
Jeffrev D. Simmons M. Diaz, K. McCollister, P. Salgueiro, L. Marques, S. Chakko, A. 
Interian, R. Myerburg, Veterans Affairs Medical Center, Miami, FL, University of Miami 
School of Medicine, Miami, FL 
Costs of evaluation, therapy and follow-up were analyzed for 29 asymptomatic patients 
with nonsustained ventricular tachycardia (NS-VT), ischemic heart disease (IHD), and 
decreased left ventricular ejection fraction (LVEF) who were undergoing electrophysio- 
logic (EP) testing for ventricular arrhythmia risk stratification. Only patients with inducible 
sustained ventricular tachycardia (VT) were treated with an implantable cardioverter 
defibrillator (ICD). Mortality data and initial costs of evaluation and therapy were 
recorded. Patients with inducible VT were then compared with “noninducible” patients in 
reference to cost of therapy and health status. 
Seventeen patients were “noninducible” and 11 patients were inducible for VT. “Nonin- 
ducible” patient follow-up included 239 patient-months and inducible VT patient follow-up 
included 232 patient-months (~~0.12). Initial costs for “noninducible” patients included 
519,605 for EP testing ($1165/patient). Two “noninducible” patients died during the fol- 
low-up period, both within 6 months of the EP testing. The 11 inducible VT patients 
accrued costs of $12,615 for EP testing, $236,500 for ICDs, and $515 for follow-up 
device interrogations. Two inducible VT patients died during the follow-up period 
(p>O.O5) at 18 months and 21 months post-ICD implant. Only 1 other patient in the induc- 
ible VT group received ICD therapy (antitachycardia pacing) and remains asymptomatic. 
Total cost for the inducible VT group was $249.630 ($22,712/patient). Incremental (addi- 
tional over “noninducible” patients) cost for inducible VT patients was 5240,015 ($21,619 
per patient). 
The inducible VT group did not experience improved survival for the increase in incre- 
mental cost per patient. Widespread application of ICD therapy to patients with 
NS-VT, IHD and decreased LVEF without screening EP testing would result in at least an 
incremental cost of $21,819 per patient. Therefore, EP testing for arrhythmic risk stratifi- 
cation appears to be justified. at least on the basis of health care cost considerations in 
our patient population. 
9:45 a.m. 
873-6 The Impact of Dual-Versus Single-Chamber Implantable 
Cardioverter-Defibrillator Implantation on Survival 
Michael Gold, Roger Freedman, David Breiter, Yunlong Zhang, Mark Schwartz, Medical 
University of South Carolina, Charleston, SC, Guidant, St. Paul, MN 
Background Prospective studies have failed to demonstrate a survival benefit with dual 
chamber (DC) pacing compared with single chamber (SC) pacing, although such a bene- 
fit has been postulated for cohorts with advanced structural heart disease. Methods: The 
LESS Study is a multicenter study evaluating low shock energy safety margins in ICD 
patients. Investigators were free to choose SC or DC ICDs. 720 patients were enrolled at 
32 investigational sites. Of 636 successfully implanted patients, 299 (47%) received DC 
ICDs and 337 (53%) received SC ICDs. There have been 65 deaths in the DC population 
during a mean follow-up of 34*13 months, and 75 deaths in the SC population during 
39i15 months. Multivariate survival analysis was performed using proportional hazards 
models to determine predictors of survival. Results: DC and SC patients differed with 
respect to age, NYHA class, the presence of atrial tachyarrhythmias. and sinus node 
dysfunction or AV block (see table). When survival is modeled vs. device type (SC or DC) 
alone, DC patients had a lower rate of survival (pcO.01, HRz1.6). However, when the 
demographic covariates are included in the model, Age (pcO.0001) and NYHA classifica- 
tion (pcO.0001) were the only covariates found to be significant predictors of survival, 
and type of device (DC or SC, p=O.43) was not significant. Conclusions: There were no 
significant differences in mortality between SC and DC patients when differences in 
demographic factors are adjusted for. 
Age 
Male 
NYHA ( Ill/IV) 
LVEF 
Sinus Node Dysfunction / AV Block 
Atrial Tachyarrhythmias 
SC (n=337) 
64.5212 
76% 
19% 
35*14 
11% 
22% 
DC (n=299) p-value 
66.7ill 0.02 
77% NS 
31% <O.OOl 
35*14 NS 
39% <O.OOl 
41% <O.OOl 
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882-i Clinical Profile and Intermediate-Term Follow-Up of 
Transvenous Pacing Leads Placed Through 
Intravascular Stents in the Young With Congenital Heart 
Disease 
Kavitha Chintala, Paul Webster, Thomas J. Forbes, Peter P. Karpawich. Children’s 
Hospital of Michigan, Wayne State University, Detroit, Ml 
Background: Intravascular stent (IS) relief of venous obstruction (obst) allows trans- 
venous pacemaker leads (PL) insertion. The purpose of this study was to review the 
intermediate follow-up of this IS/PL interaction, which remains largely unknown. Meth- 
ods: 6 patients (pts) underwent IS implant ( Palmaz 306 in 7 and lntrastent MF 1052 in 1 
) followed by 10 PL (Medtronic models 4003, 4012, 4066, 4566, 5066. 5079) inserted O- 
65 days later. Pt age ranged 9-39 years (median 17.6) and weight 27-69 kg (median 
60.5). IS was required for baffle obst in 6 pts after Mustard repair for D-transposition of 
great arteries and for innominate vein obst in 2 pts following a previous PL. Pacing was 
indicated for sinus node dysfunction in 6 pts and complete heart block in 2 pts. All pts 
received heparin during the IS implant followed by aspirin therapy for 6 months. Follow- 
up ranged from 1.3-6.3 years (median 3) and included PL assessment, catheterization, 
angiography and intravascular ultrasound. Results: There were no complications associ- 
ated with concomitant IS and PL placement. IS reduced pressure gradients across the 
obst segment from 5.13 * 2.7 to 0.66 * 1.3 mm Hg (p= 0.001) and increased vessel 
diameters from 6.2 f 3.01 to 13.7 * 1 .S mm (p= 0.001). On follow-up, all pts were asymp- 
tomatic for venous obst. None had fracture or dislodgement of the PL or IS. The pressure 
gradients were not significantly different from immediate post-implant values (2.57 * 3.5 
vs. 0.66 * 1.3 mm Hg: p= 0.3). However, IS lumens decreased from 13.7 * 1 .S to 9.2 + 
4.6 mm; p=O .03) due to neointimal growth. One pt had complete IS occlusion at 2.3 
years. In the remainina rots the mean IS intimal thickness was 1.3 f 1.03 mm and the inti- 
mal index was 0.19 * 0.17. Mean stent lumen patency among all pts was 70% at 3 years. 
IS with two PL and those with direct IS/PL contact were more likelv to be narrowed. Pac- 
ing energy thresholds (1.36 f 1.7 pJ vs. 1.35 f 2.0 pJ; p= 0.9) and impedances (638 + 
195 vs. 616 f 146 0; p=O.7) remained unchanged from implant to follow-up. Conclu- 
sions: PL can be safely inserted through IS without adverse PL performance. However 
direct IS/PL contact or two PL may contribute to increased neointimal growth and cause 
IS lumen narrowrng and obstruction. 
